ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2010
The role of lipid and carbohydrate digestive enzyme inhibitors in the management of obesity: a review of current and emerging therapeutic agents.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 145 citations in OpenAlex.
- Anti-Obesity Effects of Sulphated Polysaccharides Derived from Marine Macro Algae or Seaweeds: A Systematic Review and Meta-Analysis.Marine drugs · 2024Pooled it
- Trial
- Postprandial effects of a polyphenolic grape extract (PGE) supplement on appetite and food intake: a randomised dose-comparison trial.Nutrition journal · 2015Trial
- Lactobacillus gasseri SBT2055 suppresses fatty acid release through enlargement of fat emulsion size in vitro and promotes fecal fat excretion in healthy Japanese subjects.Lipids in health and disease · 2015Trial
- In Vitro Inhibition of Digestive Enzymes by Leaf Metabolites fromMolecules (Basel, Switzerland) · 2026Article
- Effects ofInternational journal of molecular sciences · 2026Article
- Untargeted UHPLC-HRMS Metabolomic Profiling ofAntioxidants (Basel, Switzerland) · 2025Article
- Evaluation of Aqueous Maceration and Ultrasound-Assisted Extracts ofPharmaceuticals (Basel, Switzerland) · 2025Article
- Exploring the Inhibitory Potential of Sodium Alginate Against Digestive Enzymes Linked to Obesity and Type 2 Diabetes.Molecules (Basel, Switzerland) · 2025Article
- Unraveling the Impact ofFoods (Basel, Switzerland) · 2024Article
- Establishment and Characterization of Patient-Derived Intestinal Organoids from Pediatric Crohn's Disease Patients.Pediatric gastroenterology, hepatology & nutrition · 2024Article
- Acyl pyrazole sulfonamides as new antidiabetic agents: synthesis, glucosidase inhibition studies, and molecular docking analysis.Frontiers in chemistry · 2024Article
- Effect of tea polyphenols supplement on growth performance, antioxidation, and gut microbiota in squabs.Frontiers in microbiology · 2023Article
- Antidiabetic Properties of Chitosan and Its Derivatives.Marine drugs · 2022Review
- Phlorotannins of the Brown AlgaeAntioxidants (Basel, Switzerland) · 2022Article
- Influence of traditional processing and genotypes on the antioxidant and antihyperglycaemic activities of yellow-fleshed cassava.Frontiers in nutrition · 2022Article
- Biogenic Phytochemicals Modulating Obesity: From Molecular Mechanism to Preventive and Therapeutic Approaches.Evidence-based complementary and alternative medicine : eCAM · 2022Review
- Antioxidant and Starch-Hydrolyzing Enzymes Inhibitory Properties ofMolecules (Basel, Switzerland) · 2021Article
- Phytochemical screening, antiobesity, antidiabetic and antimicrobial assessments of Orobanche aegyptiaca from Palestine.BMC complementary medicine and therapies · 2021Article
- Screening natural product extracts for potential enzyme inhibitors: protocols, and the standardisation of the usage of blanks in α-amylase, α-glucosidase and lipase assays.Plant methods · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity is a global epidemic associated with significant morbidity and mortality in adults and ill health in children. A proven successful approach in weight management has been the disruption of nutrient digestion, with orlistat having been used to treat obesity for the last 10 years. Although orlistat-induced weight loss remains modest, it produces meaningful reductions in risk factors for obesity-related conditions such as diabetes and cardiovascular disease. Moreover, this lipase inhibitor is free of the serious side effects that have dogged appetite-suppressing drugs. This success had driven investigation into new generation nutraceuticals, supplements and pharmaceutical agents that inhibit the breakdown of complex carbohydrates and fats within the gut. This review focuses on agents purported to inhibit intestinal enzymes responsible for macronutrient digestion. Except for some synthetic products, the majority of agents reviewed are either botanical extracts or bacterial products. Currently, carbohydrate digestion inhibitors are under development to improve glycemic control and these may also induce some weight loss. However, colonic fermentation induced side effects, such as excess gas production, remain an issue for these compounds. The α-glucosidase inhibitor acarbose, and the α-amylase inhibitor phaseolamine, have been used in humans with some promising results relating to weight loss. Nonetheless, few of these agents have made it into clinical studies and without any clinical proof of concept or proven efficacy it is unlikely any will enter the market soon.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.